Search reports.
Viral Vector Manufacturing Market Size, Share, Analysis 2031
Get free sample report Request for Customiztion Buy Now

Viral Vector Manufacturing Market Size, Share, Analysis 2031

Segments - Global Viral Vector Manufacturing Market by Types (Adenoviral Vectors, Retroviral Vectors, Adeno-associated Viral Vectors, and Others), Diseases (Infectious Diseases, Cancer, Genetic Disorders, and Others), Applications (Gene Therapy and Vaccinology), End-users (Research Institutes, Pharmaceutical & Biopharmaceutical Companies, and Others), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecasts, 2021-2028

https://growthmarketreports.com/Raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Rucha
Editor : Rucha Phatak

Upcoming | Report ID :CM-4419 | 4.7 Rating | 68 Reviews | 189 Pages | Format : PDF Excel PPT

Report Description


The global viral vector manufacturing market is anticipated to expand at substantial CAGR of 20.0% during the forecast period, between 2021 and 2028.

Global Viral Vector Manufacturing Market Summary

Vaccination which is used to deliver genetic coding of a specific antigen into the recipient's host cells by using viral vector is known as viral vector vaccine. In this, the strain of modified virus version which is not the virus is being targeted to transfer relevant information to the human cells. Vector virus is the virus in which there are some changes made in such a way that the human cells are able to form antibodies accordingly before the action of actual virus strain. Antigens, which are innocuous components of the virus that provoke an immune response in the body, are then produced by the cells.

  • Increasing demand for viral vector manufacturing from the pharmaceutical industry for various research purposes is fueling the market.
  • Rising prevalence of target diseases and disorders is expected to drive the demand for viral vector manufacturing in the coming years.
  • Continuous innovation is increasing costs, which in turn is expected to hamper the market growth.
  • Growing investment for gene therapy development is anticipated to provide lucrative opportunities for market players during the forecast period.

Scope of the report:

The report on viral vector manufacturing market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes

Details

Report Title

Viral Vector Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Adenoviral Vectors, Retroviral Vectors, Adeno-associated Viral Vectors, and Others), Diseases (Infectious Diseases, Cancer, Genetic Disorders, and Others), Applications (Gene Therapy and Vaccinology), End-users (Research Institutes, Pharmaceutical & Biopharmaceutical Companies, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories., uniQure N.V., F. Hoffmann-La Roche Ltd (Spark Therapeutics), FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Kaneka Eurogentec S.A., Janssen Pharmaceutica NV, AstraZeneca, Vibalogics, Sanofi, Thermo Fisher Scientific Inc. and Danaher (Cytiva)

Viral Vector Manufacturing Market Segment Insights:

The adeno-associated viral vector segment is projected to hold significant market share

In terms of types, the viral vector manufacturing market can be segregated into adenoviral vectors, retroviral vectors, adeno-associated viral vectors, and others. The adeno-associated viral vector segment is anticipated to expand at a high CAGR during the forecast period as they are used in the majority of cell-based gene treatments.

Global Viral Vector Manufacturing Market Types

The cancer segment held substantial market share in 2020

Based on diseases, the viral vector manufacturing market can be fragmented into infectious diseases, cancers, genetic disorders, and others. The cancer segment is estimated to hold majority of the global market share during the forecast period. The expanding study on viral vector gene treatments for cancer can be attributed to its significant rise.

The gene therapy segment held substantial market share in 2020

Based on applications, the viral vector manufacturing market can be bifurcated into gene therapy and vaccinology. The gene therapy segment is expected to increase at the rapid pace during the projected period. Growth of the market is attributed to availability of effective viral vector gene therapies for rare diseases and cancers, ongoing research on viral vector gene therapies, and recent approval of various viral vector gene treatments.

Global Viral Vector Manufacturing Market Applications

The pharmaceutical & biotechnology industries segment to grow during the forecast period

On the basis of end-users, the market can be segregated research institutes, pharmaceutical & biopharmaceutical companies, and others. The pharmaceutical & biopharmaceutical companies’ segment is anticipated to hold majority of the worldwide industry during the forecast period. The successful launch of viral vector gene treatments, as well as a healthy pipeline of such therapies, are significant drivers of the pharmaceutical & biopharmaceutical companies' segment.

Global Viral Vector Manufacturing Market End Users

Asia Pacific dominates the global market

In terms of regions, the global viral vector manufacturing market can be split into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific accounted for a considerable share of the market in 2020 due to leading market players' mergers and acquisitions. The rapid expansion of this geographical segment can be attributed to ongoing research initiatives aimed at launching novel gene therapies in the region's untapped markets.

Global Viral Vector Manufacturing Market Regions

Segments

Types

  • Adenoviral Vectors
  • Retroviral Vectors
  • Adeno-associated Viral Vectors
  • Others

Diseases

  • Infectious diseases
  • Cancers
  • Genetic Disorders
  • Others

Applications

  • Gene Therapy
  • Vaccinology

End-users

  • Research Institutes
  • Pharmaceutical & Biopharmaceutical Companies
  • Others

Regions

  • North America
  • Europe
  • Latin America
  • Asia Pacific
  • Middle East & Africa

Key Players

  • Lonza
  • Merck KGaA
  • Oxford Biomedica
  • CGT Catapult
  • Charles River Laboratories
  • uniQure N.V.
  • F. Hoffmann-La Roche Ltd (Spark Therapeutics)
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Kaneka Eurogentec S.A.
  • Janssen Pharmaceutica NV
  • AstraZeneca
  • Vibalogics
  • Sanofi
  • Thermo Fisher Scientific Inc.
  • Danaher (Cytiva)

Competitive Landscape

Key players in the viral vector manufacturing market include Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories., uniQure N.V., F. Hoffmann-La Roche Ltd (Spark Therapeutics), FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Kaneka Eurogentec S.A., Janssen Pharmaceutica NV, AstraZeneca, Vibalogics, Sanofi, Thermo Fisher Scientific Inc. and Danaher (Cytiva). These players engage in mergers & acquisitions, collaborations, agreements, and partnerships to strengthen their geographical presence.

Global Viral Vector Manufacturing Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Viral Vector Manufacturing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Viral Vector Manufacturing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Viral Vector Manufacturing Market - Supply Chain
  4.5. Global Viral Vector Manufacturing Market Forecast
     4.5.1. Viral Vector Manufacturing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Viral Vector Manufacturing Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Viral Vector Manufacturing Market Absolute $ Opportunity
5. Global Viral Vector Manufacturing Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Viral Vector Manufacturing Market Size and Volume Forecast by Types
     5.3.1. Adenoviral Vectors
     5.3.2. Retroviral Vectors
     5.3.3. Adeno-associated Viral Vectors
     5.3.4. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Viral Vector Manufacturing Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Viral Vector Manufacturing Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Viral Vector Manufacturing Demand Share Forecast, 2019-2026
7. North America Viral Vector Manufacturing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Viral Vector Manufacturing Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Viral Vector Manufacturing Market Size and Volume Forecast by Types
     7.4.1. Adenoviral Vectors
     7.4.2. Retroviral Vectors
     7.4.3. Adeno-associated Viral Vectors
     7.4.4. Others
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Viral Vector Manufacturing Demand Share Forecast, 2019-2026
8. Latin America Viral Vector Manufacturing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Viral Vector Manufacturing Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Viral Vector Manufacturing Market Size and Volume Forecast by Types
     8.4.1. Adenoviral Vectors
     8.4.2. Retroviral Vectors
     8.4.3. Adeno-associated Viral Vectors
     8.4.4. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Viral Vector Manufacturing Demand Share Forecast, 2019-2026
9. Europe Viral Vector Manufacturing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Viral Vector Manufacturing Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Viral Vector Manufacturing Market Size and Volume Forecast by Types
     9.4.1. Adenoviral Vectors
     9.4.2. Retroviral Vectors
     9.4.3. Adeno-associated Viral Vectors
     9.4.4. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Viral Vector Manufacturing Demand Share Forecast, 2019-2026
10. Asia Pacific Viral Vector Manufacturing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Viral Vector Manufacturing Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Viral Vector Manufacturing Market Size and Volume Forecast by Types
     10.4.1. Adenoviral Vectors
     10.4.2. Retroviral Vectors
     10.4.3. Adeno-associated Viral Vectors
     10.4.4. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Viral Vector Manufacturing Demand Share Forecast, 2019-2026
11. Middle East & Africa Viral Vector Manufacturing Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Viral Vector Manufacturing Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Viral Vector Manufacturing Market Size and Volume Forecast by Types
     11.4.1. Adenoviral Vectors
     11.4.2. Retroviral Vectors
     11.4.3. Adeno-associated Viral Vectors
     11.4.4. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Viral Vector Manufacturing Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Viral Vector Manufacturing Market: Market Share Analysis
  12.2. Viral Vector Manufacturing Distributors and Customers
  12.3. Viral Vector Manufacturing Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Lonza
     12.4.2. Merck KGaA
     12.4.3. Oxford Biomedica
     12.4.4. CGT Catapult
     12.4.5. Charles River Laboratories
     12.4.6. uniQure N.V.
     12.4.7. F. Hoffmann-La Roche Ltd (Spark Therapeutics)
     12.4.8. F

Methodology

Our Clients

General Mills
The John Holland Group
FedEx Logistics
sinopec
General Electric
Deloitte
Microsoft
Siemens Healthcare